Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Safety issue puts daclizumab in doubt for MS
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Biomarkers for Brain Disorders: Challenges and Opportunities
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Mitochondrial approaches for neuroprotection.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study

Pages